Abu Dhabi Health Data Services (ADHDS), which is part of M42’s Digital Health Solutions (DHS) platform, has announced a collaboration with Syndesis Health. This partnership is notable as Syndesis Health is one of the largest holders of phenotype data globally, with over 70 million patient profiles. The term sheet for this collaboration was signed by Kareem Shahin, CEO of M42’s Digital Health Solutions platform, and Josh Sutton, CEO of Syndesis Health. This initiative reinforces Abu Dhabi’s goal of becoming a leading hub for digital health innovation.

The collaboration aims to integrate Syndesis Health’s extensive phenotype database with ADHDS’s advanced digital health infrastructure. This integration focuses on advancements in AI-powered genomic analytics, precision medicine, and drug discovery. By leveraging real-world data along with artificial intelligence, the partnership seeks to accelerate innovation in clinical decision-making and pharmaceutical research, ultimately improving treatment pathways for patients around the world.

Three key areas will be the primary focus of this partnership. Firstly, they plan to commercialize phenotype data to support global pharmaceutical, biotech, and academic research. Secondly, they aim to develop AI-driven predictive models that foster personalized healthcare while adhering to international data governance standards. Lastly, they will enhance genomic analytics to increase prescription safety and minimize adverse drug reactions through AI-powered pharmacogenomics.

The signing of the term sheet indicates the intent to establish a joint venture that will generate valuable insights to speed up drug development and improve patient outcomes, aligning with Abu Dhabi’s vision of becoming a global leader in digital health and biomedical research. Kareem Shahin emphasized the importance of this collaboration, noting that it represents a significant advancement in utilizing real-world data and AI to transform healthcare.

Josh Sutton also highlighted that this partnership would yield groundbreaking insights to enhance pharmaceutical innovation and patient outcomes, thus setting new standards for AI-driven healthcare solutions. With both organizations committed to advancing global healthcare through data-driven innovations, this collaboration marks a crucial milestone in the fields of precision medicine and AI-powered drug discovery.